Featured Research

from universities, journals, and other organizations

Human neutrophil peptide-1: A new anti-leishmanial drug candidate

Date:
October 17, 2013
Source:
Public Library of Science
Summary:
As drug-resistant strains of Leishmaniasis spread, new non-toxic therapy could open a new front in the battle against this deadly parasite.

Leishmaniasis is a vector borne disease caused by different Leishmania species with different clinical manifestations. Cutaneous leishmaniasis (CL) is endemic and widespread especially among young individuals in Iran. Currently prophylactic or therapeutic vaccines are not available, and in spite of vector control wherever possible, the disease has not been controlled. Although the majority of zoonotic CL cases heal within 6-9 months, anthroponotic cases persist much longer. Both types leave lifelong scars that are the cause of social stigma and much morbidity; particularly important for young girls with lesions on the face or exposed area of the body. The first line drugs (antimonials) are toxic and require repeated painful injections accompanied by considerable side effects. This coupled with the development of drug resistance, recently reported in Iran, indicate the urgent need for development of new therapeutics.

Sara Dabirian, Ph.D student at Pasteur Institute of Iran, took advantage of molecules with limited toxicity to stimulate innate immune responses as a new approach to fight against leishmaniasis. Human neutrophil peptide-1 (HNP-1) is one of the most potent defensins with a broad antimicrobial activity. This peptide is naturally found within a granule of human neutrophils, a cell type that has the capacity to both kill Leishmania parasites and serve as an immediate host cell.

Using a prokaryotic expression system and an in vitro folding procedure, Dabirian et al. succeeded to cost-efficiently produce substantial amounts of active HNP-1.

The results, publishing October 17th, 2013 in PLOS Neglected Tropical Diseases, demonstrated that HNP-1 has direct leishmanicidal effects for both promastigote and amastigote and efficiently kills the parasites at concentrations non-toxic to host cells. Treatment of neutrophils with the HNP-1 was further shown to increase the life-span of the neutrophils and reduce the ability to be infected by Leishmania parasites. This was accompanied by an increase in production of the cytokine TNF-α and a reduction of the regulatory cytokine TGF-β following HNP-1 treatment of Leishmania infected neutrophils.

Professor Sima Rafati, from Molecular Immunology and Vaccine Research Laboratory at Pasteur Institute of Iran, who led the study, said: "The effects of HNP-1 on parasites and infected cells are anticipated to favorably alter the outcome of Leishmania infection. These results showed that HNP-1 holds a real potential as a candidate for a new modality of treatment for leishmaniasis." This approach may also be applicable for treatment of different forms of leishmaniasis, although it needs further investigation both in vivo and in vitro.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Sara Dabirian, Yasaman Taslimi, Farnaz Zahedifard, Elham Gholami, Fatemeh Doustdari, Mahdieh Motamedirad, Shohreh Khatami, Kayhan Azadmanesh, Susanne Nylen, Sima Rafati. Human Neutrophil Peptide-1 (HNP-1): A New Anti-Leishmanial Drug Candidate. PLoS Neglected Tropical Diseases, 2013; 7 (10): e2491 DOI: 10.1371/journal.pntd.0002491

Cite This Page:

Public Library of Science. "Human neutrophil peptide-1: A new anti-leishmanial drug candidate." ScienceDaily. ScienceDaily, 17 October 2013. <www.sciencedaily.com/releases/2013/10/131017173638.htm>.
Public Library of Science. (2013, October 17). Human neutrophil peptide-1: A new anti-leishmanial drug candidate. ScienceDaily. Retrieved August 31, 2014 from www.sciencedaily.com/releases/2013/10/131017173638.htm
Public Library of Science. "Human neutrophil peptide-1: A new anti-leishmanial drug candidate." ScienceDaily. www.sciencedaily.com/releases/2013/10/131017173638.htm (accessed August 31, 2014).

Share This




More Health & Medicine News

Sunday, August 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com
California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

California Passes 'yes-Means-Yes' Campus Sexual Assault Bill

Reuters - US Online Video (Aug. 30, 2014) California lawmakers pass a bill requiring universities to adopt "affirmative consent" language in their definitions of consensual sex, part of a nationwide drive to curb sexual assault on campuses. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
3 Things To Know About The Ebola Outbreak's Progression

3 Things To Know About The Ebola Outbreak's Progression

Newsy (Aug. 29, 2014) Here are three things you need to know about the deadly Ebola outbreak's progression this week. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins